Board to consider Interim Dividend
Zydus Wellness Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on March 04, 2016, to consider, the proposal for declaration of Interim Dividend, if any, for the financial year 2015-2016 and fixing Record Date for the purpose.Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window will... Zydus gets final USFDA nod for anti-diabetic Glyburide, Metformin
Pharma major Cadila Healthcare Ltd (Zydus Cadila)on Tuesday said it has received final approval from the United States Food and Drug Administration (USFDA) to market anti-diabetic drugs called ... Zydus gets USFDA nod to market Doxycycline Capsules USP
Zydus Cadila on Friday announced that the company has received approval from the US drug regulator, US Food and Drug Administration to market Doxycycline Capsules USP. In a statement here, the co... Indians are late to the biologicals party
but because of that, we can use newer and better technology, says Zydus Cadilas COO Financial Results with Results Press Release & Limited Review Report for Dec 31, 2015
Zydus Wellness Ltd has informed BSE about :1. Financial Results for the period ended December 31, 2015 (Standalone and Consolidated).2. Limited Review Report for the period ended December 31, 2015 (Standalone and Consolidated).3. Results Press Release. Board Intimation for Results & Closure of Trading Window
Zydus Wellness Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on February 04, 2016 to consider apart from other agenda items to approve the unaudited financial results [limited reviewed] for the quarter / nine months ended on December 31, 2015.Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015, the... Shareholding for the Period Ended December 31, 2015
Zydus Wellness Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2015. For more details, kindly Click here Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015
Zydus Wellness Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Zydus Cadila acquires select animal health brands of Zoetis
Company said a major boost to Zydus's portfolio will be addition of livestock farmcare products Authorised KMPs to determine materiality of events/information
Zydus Wellness Ltd has informed BSE regarding "Authorised Key Managerial Personnel to determine materiality of events/information".